Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2020 16:05 ET | Source: Oncocyte Corporation

Oncocyte Reports Third Quarter 2020 Financial Results and Provides Corporate Update

DetermaRx™ receives final CMS pricing and records first full quarter with Medicare revenues; more than doubles second quarter volumes with adoption at NCCN and NCI designated cancer centers ...
November 09, 2020 16:05 ET | Source: Oncocyte Corporation

Oncocyte to Present DetermaIO™ Test Data at the 2020 Society for Immunotherapy of Cancer (SITC) Conference

IRVINE, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
November 02, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte to Report Third Quarter 2020 Financial Results on Thursday, November 12

IRVINE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
October 28, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte Named One of the 2020 Best Places to Work in Orange County in Its First Year in Irvine, CA

IRVINE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
October 20, 2020 17:21 ET | Source: Oncocyte Corporation

Oncocyte Announces Third Quarter Growth of DetermaRx™ Physician Adoption and Testing Volume

Testing volume for DetermaRx more than doubled in Q3 2020 Growing hospital and physician adoption at large community practices and National Comprehensive Cancer Network (NCCN) and NCI-designated...
October 14, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte Announces New Prospective Data Demonstrating That Treatment Informed by DetermaRx™ Significantly Improves Lung Cancer Patient Survival

Data to be Presented by Dr. Gavitt Woodard of Yale University at the IASLC 2020 North America Conference on Lung Cancer Results and Clinical Utility to be Discussed During KOL Webinar on October 22nd...
October 08, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte and Fondazione Michelangelo, a Leading Non-Profit Cancer Research Foundation, Announce Immune Therapy Biomarker Collaboration

Investigator-sponsored trial to evaluate DetermaIO™ as a biomarker of neoadjuvant checkpoint inhibitor response in triple-negative breast cancer (TNBC) Collaboration to generate near-term...
October 01, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

Chronix’s blood-based test monitors the effectiveness of immunotherapy drugs in clinical trials, and potentially in patients receiving immunotherapy treatment Further extends Oncocyte’s product...
September 14, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte to Participate at the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference

IRVINE, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
September 09, 2020 08:00 ET | Source: Oncocyte Corporation

Oncocyte Receives Final Pricing Decision for DetermaRx™ Molecular Test for Lung Cancer from Centers for Medicare and Medicaid Services

Pricing in line with comparable high-value molecular tests for oncology indications Consistent growth in testing volumes now provides immediate and consistent revenue for Oncocyte DetermaRx is...